AstraZeneca’s SGLT2 inhibitor Farxiga is already a big hit in heart failure but is now set to bring in even more revenues thanks to a first-in-class approval in chronic kidney disease (CKD).
The US Food and Drug Administration gave the green light for Farxiga (dapagliflozin) on 30 April as a treatment to...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
